24 results about "Carcinoma bladder" patented technology

The invention belongs to the technical field of traditional Chinese medicine biology, and particularly relates to a pair of diastereoisomers in fresh bamboo juice as well as a preparation method and application of the diastereoisomers, in the diastereoisomers, a formula I is a dextroisomer and is named as (+)-fresh bamboo juice phenol A, and a formula II is a levoisomer and is named as (-)-fresh bamboo juice phenol A. According to the invention, a pair of diastereoisomer compounds (+)-fresh bamboo juice phenol A and (-)-fresh bamboo juice phenol A are successfully obtained from fresh bamboo juice, and an in-vitro cell test shows that the (+)-fresh bamboo juice phenol A has a remarkable inhibition effect on gastric cancer cells, liver cancer cells, colorectal cancer cells, bladder cancer cells and lung cancer cells of a human body; the compound can be used for preparing medicines for preventing or treating tumors, and has a wide application prospect.

The invention relates to a triple-hole paper-based three-dimensional cell culture chip as well as a preparation method and application thereof. The chip comprises a paraffin hydrophobic region and a paper-based hydrophilic region. The preparation method mainly comprises the following steps: 1) designing a mask plate; 2) cutting the mask plate by laser; and 3) preparing the triple-hole paper-based chip by hot pressing. The thickness of the chip is 100-200 [mu] m, the porous fiber structure of the paper-based material allows transportation of oxygen and waste, and a three-dimensional microenvironment for in-vivo cell growth can be simulated. Meanwhile, a transparent and liquid-tight supporting layer is fused on the lower layer of the paper-based chip, so that leakage of cells inoculated on the upper layer of the paper-based chip is avoided. The paper-based chip is embedded into a 6-pore plate, and bladder cancer cells (5637), mouse astrocytoma (U87) and human breast cancer cells (MCF-7) are inoculated in a paper-based hydrophilic region respectively. The cell compatibility of the paper-based chip and the growth behaviors of three different types of cells in three-dimensional paper fibers are investigated. It is proved that the chip can be used for researching three-dimensional construction and growth of human and mammalian cells, and the difference between three-dimensional culture and two-dimensional culture is revealed by detecting the proliferation capacity and survival rate of different cells.

The invention provides a human bladder cancer vedicetumab drug-resistant cell strain as well as a construction method and application thereof. The cell strain is named as a human bladder cancer drug-resistant cell strain T24-RC48, and the preservation number of the cell strain is CCTCC (China Center For Type Culture Collection) NO: C2024180. During construction, a method of continuously inducing at low concentration and gradually increasing the drug concentration and the treatment time of the RC48 is adopted, so that the formation of the RC48 drug-resistant cells is effectively induced, and the construction method is simple to operate and can effectively make up for the defects of the existing method. The human bladder transitional cell carcinoma RC48 drug-resistant cell strain T24-RC48 constructed by the invention can be used for researching a bladder cancer drug-resistant mechanism, promoting the development of predictive biomarkers, evaluating the antitumor activity of drugs and preparing a tumor cell model or a tumor animal model; a cell research model is provided for screening, researching and developing effective drugs and methods for overcoming bladder cancer drug resistance, and good application prospects are achieved.

A computer-implemented method for identifying bladder cancer cells includes: receiving a microscopic image of a specimen imaging a plurality of cells; analyzing a quality of the microscopic image; classifying the cells imaged on the microscopic image to indicate potentially cancerous cells; analyzing the whole microscopic image to determine an overall probability that the microscopic image comes from a potentially cancerogenous patient, based on distribution of the potentially cancerogenous cells; presenting, on a single screen of a graphical user interface of a computer system: an overall image representing box and a plurality of cell identification boxes; receiving on said single screen an expert input; repeating the step of analyzing; and generating a final report that identifies an overall probability that the microscopic image comes from a potentially cancerogenous patient.

This invention relates to the field of cell detection equipment technology, specifically to a detection device for bladder cancer metabolomics biomarkers. The device includes an ELISA reader, a moving stage, and well plates housed within it. It also includes a defoamer mounted on the outer wall of the ELISA reader. The defoamer comprises a fixing part, a pair of transmission parts, and a striking part and an air blowing part disposed within the fixing part. This bladder cancer metabolomics biomarker detection device, through a mechanical linkage design between the moving stage and the defoamer, uses a gear-driven toothed plate to move a dial-driven bending plate up and down, causing a striking rod to strike the well plate. Combined with synchronous airflow from the air blowing part, a protrusion pushes a piston plate within a second groove, directing airflow from the nozzle. This achieves automated removal of air bubbles from the wells before ELISA reader detection. The dual defoaming effect of striking vibration and airflow impact eliminates optical interference, ensuring the accuracy of the detection values ​​and simplifying the detection process.

This invention discloses a chimeric guide RNA integrating RNA interference and CRISPR-Cas13d and its applications. Utilizing the structural matching between shRNA and Cas13d crRNA, this invention embeds the complete Cas13d crRNA into the classic shRNA backbone, constructing a dual-pathway synergistic silencing chimeric guide RNA (SS-Rx). Experiments have demonstrated that SS-Rx possesses the dual activity of shRNA and CRISPR-Cas13d, exhibiting superior gene silencing efficiency compared to traditional RNA silencing tools, and can inhibit the proliferation, migration, and invasion of bladder cancer cells by suppressing tumor-related genes. This invention synergistically combines the advantages of RNA interference and CRISPR-Cas13d, providing an efficient and widely applicable framework for gene function research and RNA-targeted therapy, with significant economic benefits and broad application prospects.

The invention discloses a bladder tumor cell strain with squamous differentiation characteristics and application thereof, and relates to the technical field of biological medicines. Wherein the bladder tumor cell strain is selected from one of a human bladder tumor cell strain MP-MGHU3-LT, a human bladder tumor cell strain UCSD-MGHU3-LT, a human bladder tumor cell strain UCSD-RT4-LT and a mouse bladder tumor cell strain mUCMP, the bladder tumor cell strains are all preserved in the China Center for Type Culture Collection, and the preservation numbers of the bladder tumor cell strains are respectively CCTCC NO: C2025241, CCTCC NO: C2025252, CCTCC NO: C2025253 and CCTCC NO: C2025254. The bladder tumor cell strain provided by the invention has squamous differentiation characteristics, and can be applied to model construction, mechanism research and drug screening of bladder cancer with squamous differentiation characteristics.

The application relates to a bladder cancer fine typing method and system based on nucleic acid aptamer differential analysis, which comprises the following steps: incubating a sample containing bladder cancer cells through a probe package, and performing high-throughput gene sequencing on the incubated sample to obtain sequencing data; removing abnormal samples from the sequencing data to obtain nucleic acid aptamer data; standardizing the nucleic acid aptamer data to obtain standard data including a health sample group and a case sample group; selecting differential expression aptamers from the standard data; and typing a to-be-tested sample through the differential expression aptamers. The application can identify the expression difference of specific nucleic acid aptamers in bladder cancer cells, and further realizes fine typing.

There is provided the combination of Bacillus Calmette-Guérin (BCG) vaccine and β-glucan adjuvant for the treatment of a cancer characterized by the presence of protumoral T3 neutrophils in the tumour microenvironment. The β-glucan is characterized by a μ-1,3 glucose backbone. The BCG and β-glucan combination demonstrated a synergistic effect in remodeling the tumour microenvironment to resist conversion of neutrophils into the T3 phenotype. The cancer can be bladder cancer, melanoma, lung adenocarcinoma, head and neck squamous cell cancer, pancreatic adenocarcinoma, low-grade gliomas, esophageal carcinoma, and cervical squamous cell carcinoma.

The present invention belongs to the field of traditional Chinese medicine biotechnology, and specifically relates to a phenolic compound, its preparation method and application. The phenolic compound is a pair of diastereoisomers, where Formula I is the dextrorotatory form, named (+)-fresh bamboo juice phenol B, and Formula II is the levorotatory form, named (−)-fresh bamboo juice phenol B. The present invention successfully obtained a pair of diastereoisomeric phenolic compounds, (+)-fresh bamboo juice phenol B and (−)-fresh bamboo juice phenol B, from fresh bamboo juice. Through in vitro cell experiments, it was found that both of them have significant inhibitory effects on human gastric cancer cells, liver cancer cells, colorectal cancer cells, bladder cancer cells and lung cancer cells, and can be used in the preparation of drugs for preventing or treating tumors, showing broad application prospects.

The invention relates to the technical field of recombinant bacillus calmette guerin vaccines, in particular to a gene knockout attenuated granulysin / IL-12 recombinant plasmid, a recombinant bacillus calmette guerin and application. The nucleotide sequence of the recombinant plasmid is shown as SEQ ID NO: 1, and the recombinant plasmid contains IL-12 and GLS gene segments. The gene knockout attenuated granulysin / IL-12 recombinant bacillus calmette guerin vaccine contains the recombinant plasmid disclosed by the invention. The TrpD gene of the BCG is knocked out and is combined with an IL-12 / GLS double-gene eukaryotic expression system to construct a recombinant BCG strain, so that the dual functions of effect enhancement and toxicity reduction are realized, and the BCG strain is used for treating bladder cancer. The TrpD gene of the BCG is knocked out, the toxicity of the BCG is reduced, the disseminated infection risk is reduced, and the safety is improved; th1 immune imbalance is corrected, the anti-tumor effect is enhanced, tumor microenvironment Th1 type immune remodeling is induced through IL-12, and the anti-tumor effect is enhanced; a double-gene expression system is adopted, synergistic interaction is achieved, an IL-12 / GLS double-gene expression system is integrated, IL-12 regulates Th1 unbalance, and GLS directly induces tumor cell apoptosis.

The invention provides an exosome preparation with a treatment function and a preparation method thereof, and belongs to the technical field of cell biology. The exosome preparation is prepared by subjecting stem cells to first-stage alpinetin stimulation and second-stage low-intensity magnetic field stimulation, and can effectively inhibit bladder cancer cell proliferation and migration and enhance the sensitivity of bladder cancer cells to chemotherapy drug paclitaxel, so that a novel biological treatment strategy is provided for overcoming bladder cancer chemotherapy drug resistance; the important clinical transformation value is realized.

The invention belongs to the field of gene engineering, and particularly discloses an application for inhibiting proliferation and growth of cancer cells by expressing and connecting an H1.4 C terminal of a histone H1 family member, especially for lung cancer and bladder cancer cells. In the invention, a specific nucleic acid fragment is designed to encode the histone fragment, and a plasmid containing the nucleic acid fragment is constructed. Furthermore, the plasmid is packaged by utilizing a lentiviral vector technology, so that a target gene is efficiently introduced into a cell, and a cell model for expressing the terminal fragment of the histone H1.4 C is established. Meanwhile, the invention provides a specific primer sequence for constructing the cell model.

The invention relates to a bladder cancer fine typing method and system based on aptamer difference analysis, and the method comprises the steps: incubating a sample containing bladder cancer cells through a probe package, and carrying out high-throughput gene sequencing on the incubated sample to obtain sequencing data; performing abnormal sample removal on the sequencing data to obtain aptamer data; performing standardization processing on the aptamer data to obtain standard data including a healthy sample group and a case sample group; selecting a differential expression aptamer from the standard data; and typing a to-be-detected sample through the differential expression aptamer. According to the present invention, the expression difference of the specific nucleic acid aptamer in the bladder cancer cell can be identified so as to achieve the fine typing.

GD2-specific chimeric antigen receptor effector cells for the treatment of solid tumors, which can be combined with an Enhancer of Zeste Homolog 2 (EZH2) inhibitor. ------ The present invention relates to GD2-specific chimeric antigen receptor (GD2.CAR) effector cells for the treatment of both solid tumors, particularly extracranial GD2+ tumors (such as soft tissue sarcomas and osteosarcomas, neuroblastomas, melanomas, lung cancers, bladder cancers, and retinoblastomas) and brain tumors. Furthermore, the present invention also relates to the use of GD2.CAR gene-modified effector cells in combination with an Enhancer of Zeste Homolog 2 (EZH2) inhibitor in the treatment of solid tumors.

The invention discloses a novel polypeptide fluorescent probe as well as a preparation method and application thereof, and belongs to the field of biomedical technology and fluorescence imaging. The novel polypeptide fluorescent probe is sequentially connected with a targeted recognition module, an enzyme response module, a self-assembly module and a functional module through amido bonds. The targeted recognition module is used for recognizing a CD44v6 specific receptor highly expressed on bladder cancer cells, the enzyme response module is a specific polypeptide sequence of MMP2 enzyme, and the functional module is a biological orthogonal group. The polypeptide fluorescent probe disclosed by the invention is targeted on the surface of a bladder cancer cell through a specific recognition sequence, and nano-fibers are formed through enzyme response shearing and in-situ self-assembly and are adhered on the surface of the cell to form an artificial receptor similar to the surface of the cell; then, fluorescent molecules are delivered to be subjected to a click chemical reaction with biological orthogonal groups exposed outside the nanofibers, so that high-imaging signal-to-noise ratio visual tumor positioning of a tumor area is realized, and a new method is provided for surgical precise excision of bladder cancer.

The invention discloses a method, a system, equipment and a medium for identifying tumor biomarkers. The method comprises the following steps: retrieving and analyzing a TCGA database, and obtaining circRNA data sets of a target tumor sample and a healthy person sample; marking all circRNAs expressed in the target tumor sample but not expressed in the healthy sample as a first class, and marking all circRNAs expressed in both the target tumor sample and the healthy sample as a third class; screening circRNA of which the sample ratio is higher than a first preset threshold value and the average expression quantity is greater than a second preset threshold value from the first class, and marking the circRNA as a biomarker of the target tumor; screening circRNA with significant expression difference between the target tumor sample and the healthy sample from the third class, and marking the circRNA as a candidate biomarker; and screening the biomarker of the target tumor from the candidate biomarkers by adopting a feature selection technology and a deep learning algorithm. According to the invention, circRNA which can be used for early diagnosis and prognosis evaluation of bladder cancer can be accurately identified as a biomarker.

The present invention discloses biomarkers of colorectal cancer tumor border cell subpopulations and their applications in diagnosis, prevention, treatment and prognosis. The present invention also discloses a microenvironment cell map of adjacent and cancerous tissues of colorectal cancer patients, in which FAP is specifically enriched in colorectal cancer tissues. + Fibroblasts and SPP1 + The present invention also discloses FAP + Fibroblasts and SPP1 + The present invention further discloses that patients with high expression of these two proteins in bladder cancer data sets also have a lower response rate to PD-L1 treatment. The present invention also discloses FAP + Fibroblasts and SPP1 + Macrophages are also spatially localized in colorectal cancer, forming a "wall"-like tumor boundary around the tumor center, thereby preventing immune cells from entering the tumor center. These cellular characteristics and cell interaction patterns can be used to effectively diagnose, prevent, treat, and assess prognosis and survival for CRC.

The invention provides an application of cistanche glycoside F or pharmaceutically acceptable salts thereof in preparation of antitumor drugs. In-vitro experiments show that the cistanoside F has remarkable inhibitory activity on various tumor strains such as human lung cancer cells A549, human gastric adenocarcinoma cells AGS-CAS9, human liver cancer cells SK-HEP-1, human bladder cancer cells RT112, human cervical cancer cells Hela, human prostate cancer cells PC-3, human neuroblastoma cells SH-SY5Y and the like. Animal tests show that cistanche glycoside F has a good in-vivo anti-tumor effect and has a remarkable treatment effect on various tumors such as bladder cancer and liver cancer. The cistanche glycoside F is high in anti-tumor activity and has a wide application prospect.

The invention discloses a DNA (deoxyribonucleic acid) aptamer enzyme for detecting a high-expression glycosylated PD-L1 cell line, and relates to the field of biological and medical detection. The method comprises the following steps: connecting a DNA pool with a shearing substrate under the assistance of a template, reacting with A549Degly, separating to generate sheared and unsheared molecules by using polyacrylamide gel, retaining the unsheared molecules, taking a lung cancer cell line A549 as a background cell, reacting with a connecting product, and separating the sheared molecules by using the polyacrylamide gel, thereby obtaining the lung cancer cell line A549. And the RFD probe for detecting the glycosylated PD-L1 is screened out. The probe is the first RFD probe for detecting the glycosylated protein; the RFD probe has the potential to be expanded and applied to detection of other glycosylation receptor proteins; the RFD probe is used for clinical pathology PD-L1 detection of carcinoma in situ, and the CTC capture magnetic nano device can be established by using nucleic acid aptamers of different tumors and is used for PD-L1 detection of various metastatic cancers such as liver cancer, melanoma, renal cell carcinoma, head and neck squamous cell carcinoma and bladder cancer.

The invention discloses novel 5-substituted 4-hydroxy-cyclopent-2-en-1-one derivatives as active compounds in pharmaceutical compositions for the treatment of cancer. The invention confers cytotoxic effects of the said compounds on ovarian, colorectal, cervical, hepatocellular, lung, bladder and breast carcinomas, melanoma, lymphoma, leukemia and myeloma malignant cells, for the inhibition of cell cycle progression at the G2 / M phase, for reducing the expression of DNA replication licensing factors and for having general cancer treatment effects. It further discloses the use of the said compositions for the treatment of platinum-resistant tumors. Another aspect of the invention is the synergetic effects of these compounds with existing cancer treatment medicaments as the proteasomal inhibitors. Finally, the synthetic methods of the active compounds of the said com-positions are disclosed.

The invention discloses a method for simultaneously detecting bladder cancer cells in photoelectrochemical / photo-thermal dual modes. The method is characterized by comprising the following steps: (1) preparing CuO-coated NPC-Apt; 2) construction of a PEC / PT dual-mode biosensing platform; and 3) PEC / PT dual-mode simultaneous detection of bladder cancer cells. The CuO-coated NPC is used as a dual-signal probe of a PEC / PT dual-mode sensing platform, and in the presence of bladder cancer cells, the CuO-coated NPC not only has photoelectrochemical signal response, but also can carry out photo-thermal imaging and temperature output analysis, so that the bladder cancer cells are simultaneously detected in dual modes. The kit has the advantages of high sensitivity, strong specificity, good accuracy and simplicity and rapidness in operation.

The invention belongs to the technical field of medicines, and particularly relates to a dehydrocostus lactone derivative as well as a preparation method and application thereof. The structure of the dehydrocostus lactone derivative is as shown in formula I in the specification. The compound has a remarkable proliferation inhibition effect superior to dehydrocostus lactone on human lung cancer cells, human liver cancer cells, human colon cancer cells, human esophageal cancer cells, human renal clear cell adenocarcinoma cells, human bladder cancer cells, human prostate cancer cells, human breast cancer cells and human brain tumor cells. The compound especially has an obvious colon cancer resisting effect, can induce concentration-dependent arrest of HCT116 cells in a G0 / G1 phase, and simultaneously causes early apoptosis and late apoptosis of the HCT116 cells in a concentration-dependent manner. The dehydrocostus lactone derivative has a wide application prospect in preparation of antitumor drugs. And # imgabs0 #.

The invention belongs to the technical field of cell extraction, and provides a bladder cancer stem cell biomarker extraction method, which comprises: in the historical extraction of bladder cancer stem cell biomarkers, obtaining a plurality of biomarker concentrations of each operation, then according to the biomarker concentrations, carrying out effective degree evaluation on each operation, constructing a historical feature library according to an evaluation result, performing extraction stability analysis on a plurality of biomarkers in the historical feature library to obtain a stability analysis result, and constructing a stable extraction feature library according to the stability analysis result, so that the extraction stability of the biomarkers is comprehensively analyzed from two dimensions of extraction times and extraction concentration; accurate data support is provided for screening and extracting biomarkers with high stability and bringing the biomarkers into a stable extraction feature library, the reliable stable extraction feature library is constructed, and more stable and accurate biomarker features are provided for subsequent application such as research and diagnosis.